Thursday | ||||
Stifel analyst Justin… Stifel analyst Justin Keywood initiated coverage of Kneat.com with a Buy rating and C$3.75 price target. Kneat operates an end-to-end SaaS platform that manages the validation or compliance process in pharmaceutical manufacturing and serves eight of the world's top 10 global pharma companies in transitioning mostly paper-based systems to digital, said Keywood, who sees the stock offering "a good combination of defense and offense." |